This article is more than 5 years old. Information may no longer be current.
RTI Surgical announces two new bone grafting solutions
Click Here to Manage Email Alerts
RTI Surgical Inc. recently announced in a press release their launch of two new biological solutions.
The first is NanOss Bioactive 3D, a synthetic 3-D bioscaffold that uses a semi-rigid 3-D scaffold consisting of porous hydroxyapatite granules suspended within a porous gelatin-based foam matrix to support bone formation in a wide range of extremity and trauma surgical procedures.
Map3 Cellular Allogeneic Bone Graft is RTI Surgical’s second new product. It is an implant comprised of cortical cancellous chips, demineralized bone matrix and viable adult stem cells, and contains the essential elements needed to generate and maintain new bone in a single allograft.
“We are excited to launch these two bone graft solutions,” Brian K. Hutchison, RTI Surgical’s president and chief executive officer, stated in the press release. “NanOss Bioactive 3D, a synthetic bone graft, and map3 Cellular Allogeneic Bone Graft, a human tissue bone graft, showcase the broad portfolio of surgical implants offered by RTI Surgical.”